All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Multimodal AI Approach May Help Identify Key Elements to Predict Outcomes in RCC

July 11th 2024

Using an AI tool for the collection and analysis of patient data may enhance the accuracy of outcome predictions and help personalize treatment plans.

Nivolumab Plus Ipilimumab Yields Long-Term Efficacy Advantage in Advanced RCC

July 11th 2024

Nivolumab plus ipilimumab may generate positive long-term outcomes in patients with advanced renal cell carcinoma regardless of IMDC risk status.

Observational MOST Trial Reveals Progression Trends in Low-Risk Myelofibrosis

July 11th 2024

Aaron Gerds, MD, discusses progression data for patients with low- or intermediate-1–risk myelofibrosis in the MOST trial.

Roswell Park Insights on Role of Exportin 1 Protein Suggest Strategy for Improving Cancer Immunotherapy

July 11th 2024

Research team shares new data on how XPO1 blockade may boost immune-based treatments.

SLS009 Earns EMA Orphan Drug Designation for AML

July 11th 2024

SLS009 has been granted orphan drug designation by the EMA for the treatment of patients with acute myeloid leukemia.

Dual Targeting of the mTOR Pathway May Enhance Antitumor Activity in Solid Malignancies

July 11th 2024

Recent studies of novel mTOR inhibitors in combination with various agents have shown how these combinations may be used for patients with solid tumors.

Tarlatamab Monotherapy Is Safe, Active in DLL3+ Neuroendocrine Prostate Cancer

July 11th 2024

A 100-mg dose of tarlatamab was safe and showed particularly robust activity in patients with DLL3-positive neuroendocrine prostate cancer.

FS-1502 Is Safe and Displays Antitumor Activity in Metastatic HER2+ Breast Cancer

July 11th 2024

The HER2-directed ADC FS-1502 was well tolerated and generated early signals of antitumor activity in patients with HER2-expressing breast cancer.

Subanalysis Supports Imetelstat for Transfusion-Dependent Low- to Intermediate-1–Risk MDS

July 10th 2024

Mikkael A. Sekeres, MD, discusses the FDA approval of imetelstat for patients with low- to intermediate-1–risk MDS, highlighting data from a subanalysis.

Phillips Discusses Past Progress and Previews the Future in Hematologic Cancers

July 10th 2024

Tycel Phillips, MD, highlights key takeaways in NHL, MDS, and myelofibrosis from an OncLive State of the Science Summit on hematology.

Fox Chase Cancer Center Appoints Dr. Jeffrey M. Farma Chair of Surgery

July 10th 2024

Jeffrey M. Farma, MD, FACS, has been appointed Chair of Surgery at Fox Chase Cancer Center.

Paxalisib Continues to Provide Survival Benefit Over SOC in Newly Diagnosed Unmethylated Glioblastoma

July 10th 2024

Paxalisib improved OS over SOC in patients with newly diagnosed glioblastoma and unmethylated MGMT promotor status.

FDA Approval Sought for Another Formulation of Lutetium Lu 177 Dotatate in SSTR+ GEP-NETs

July 10th 2024

Curium has submitted an NDA to the FDA for its formulation of lutetium Lu 177 dotatate for SSTR-positive gastroenteropancreatic neuroendocrine tumors.

HyBryte Continues to Improve mCAILS in Early Cutaneous T-Cell Lymphoma

July 10th 2024

Up to 12 months of treatment with SGX301 produced lesion responses in patients with early-stage cutaneous T-cell lymphoma.

New Data Augment the Treatment Paradigm in HR+/HER2– Breast Cancer

July 10th 2024

Panelists from an OncLive Peer Exchange detail updated data in the hormone receptor–positive HER2– breast cancer treatment landscape.

Nivolumab/Ipilimumab Yields Responses in Ovarian Clear Cell Carcinoma

July 10th 2024

Don Dizon, MD, discusses updated findings from the BrUOG 354 trial and the future of immunotherapy for patients with ovarian cancers.

Neoadjuvant Cemiplimab Underscores Push to Bolster Treatment of CSCC

July 10th 2024

Neil D. Gross, MD, FACS, discusses the neoadjuvant use of cemiplimab for the treatment of cutaneous squamous cell carcinoma.

Durable Responses With GLPG5101 Suggest Feasibility of Decentralized CAR T Manufacturing in R/R NHL

July 9th 2024

GLPG5101 produced high CRs in patients with relapsed/refractory non-Hodgkin lymphoma, indicating the feasibility of decentralized CAR T manufacturing.

OBX-115 Earns FDA Fast Track Designation for Advanced Melanoma

July 9th 2024

The FDA has granted fast track designation to OBX-115 for advanced melanoma that is refractory to or relapsed after immune checkpoint inhibitors.

Researchers Report First Effective Use of Immunotherapy for Most Common Subtype of Colorectal Cancer

July 9th 2024

Botensilimab plus balstilimab generated responses in relapsed/refractory microsatellite stable metastatic colorectal cancer.